Preclinical study conducted by Goel et al. has shown immune-modulatory effects of CDK4/6i by increasing interferon production, improving tumor antigen presentation, suppressing Treg proliferation, and increasing tumor infiltration and the activation of effector T cells, thus potentially enhancing the response to ICIs [30]. This evidence concerns the gene CDK4 and neoplasm.